tbuckley/cabot-search huggingface dataset:
Sequential Measurement Of JAK2 V617F Allele Burden In Polycythemia Vera and Essential Thrombocythemia Reveals Different Evolution Profiles: First Results Of Jaksuivi, a Multicentre Study By The French Intergroup Of Myeloproliferative Neoplasms (FIM)
Authors: Caroline Buors, Françoise Boyer, Aline Tanguy-Schmidt, Aurélie Chauveau, Lydia Roy, Jean-Claude Chomel, Thierry Lamy, Olivier Fardel, Olivier Herault, Laura Samaison, Valérie Ugo, Jean-Christophe Ianotto
Journal: Blood (2013)
Outpatient initiation and rotation to methadone in palliative care patients with cancer-related pain
Authors: B. E. El Osta, H. A. Parsons, B. B. Calderon, T. Paraskevopoulos, L. E. Roberts, L. Navarrete, E. Ramirez, Z. Li, J. L. Palmer, E. Bruera
Journal: Journal of Clinical Oncology (2008)

9587 Background: Methadone is an effective and very inexpensive opioid for cancer pain treatment. It has been reported as difficult to use in the outpatient setting due to its variable relative potency and long half-life. The purpose of this study was to determine the outcome of methadone initiation for cancer pain treatment in our palliative care outpatient center. Methods: 189 consecutive patients were either initiated or rotated to methadone in the outpatient center by our palliative care physicians after April 2003. We reviewed their medical charts for demographics and clinical characteristics, symptoms, opioid side effects, and toxicities at baseline, first (F1), and second follow up (F2). Failure was defined as methadone discontinuation by the palliative care physician or patient’s hospitalization for uncontrolled pain or methadone related side effects. Results: 100 (53%) patients were female, 138 (73%) were white, 182 (96%) had solid cancers, 80 (42%) had neuropathic pain. Median age was 60 years. 100 (53%) were initiated on methadone and 89 (47%) patients were rotated from other strong opioid to methadone. The main reason for rotation was pain (65 patients, 47%). Median (range) pain scores (Edmonton Symptom Assessment System 0–10, ESAS) were 6 (0–10), 4 (0–10), and 3 (0–10) at baseline, F1, and F2, respectively (p<0.0001). Median (range) nausea scores (ESAS) were 1 (0–10), 0 (0–8), and 0 (0–8) at baseline, F1, and F2, respectively (p=0.04). Median drowsiness scores (ESAS) were 2 (0–10), 3 (0- 10), and 2 (0–10) at baseline, F1, and F2, respectively (p=ns). The success rates for methadone initiation and rotation to methadone were 82/89 (92%) and 84/100 (84%), respectively. Median methadone dose was 10mg/day at F1 and 15mg/day at F2. Constipation improved significantly (p=0.004) with the rotation to methadone. Side effects such as sedation, hallucinations, myoclonus, and delirium showed a trend towards improvement after initiation or rotation to methadone. Conclusions: Outpatient methadone initiation and rotation for cancer pain treatment were safe, with high success rate and low side effect profile. No significant financial relationships to disclose.
A phase II trial of biweekly gemcitabine and paclitaxel (GEMTAX) combination in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): A Southwest Oncology Group study.
Authors: K. E. Bickel, F. P. Worden, J. Moon, O. Kucuk, R. H. Wheeler, J. Clark, G. T. Wolf, S. Urba
Journal: Journal of Clinical Oncology (2010)

5555 Background: Combinations of gemcitabine (G) and paclitaxel (P) have documented efficacy in lung, bladder, and breast cancer. Based on prior phase I data and pilot data of this regimen in advanced SCCHN, we conducted a multicenter phase II study to assess the efficacy and safety of biweekly GEMTAX in patients (pts) with recurrent or metastatic SCCHN. Methods: Eligible pts had biopsy proven SCCHN, either metastatic or persistent/recurrent after definitive surgery or radiation therapy. Pts also had Zubrod PS ≤ 1, sensory neuropathy < grade (Gr) 2, no serious organ dysfunction or CNS metastases. One prior induction or adjuvant regimen was allowed, with no G or taxanes, completed at least 6 months prior to enrollment. Treatment was G 3,000 mg/m2 and P 150 mg/m2 on days 1 and 15 of a 28 day cycle. Response to treatment was evaluated every 2 cycles. Treatment continued for 4 cycles after confirmed complete response or until disease progression. Results: 63 eligible pts (50 males, 13 females), median age 63.1 (range 40.7-82.9), were enrolled from 19 SWOG institutions. Major primary sites: 20 lip/oral cavity, 13 oropharynx, and 16 larynx. Status at enrollment: 50 recurrent, 7 persistent, 5 newly diagnosed. Response in 57 pts with measurable disease was 2 complete and 13 partial responses, for an estimated response rate of 26% (95% CI 16-40). The median times to overall and progression free survival were 8 months (95% CI 7-11) and 4 months (95% CI 3-6), respectively. Among 8 pts alive at last contact the median follow-up was 39 months (range 26-54). There were no treatment related deaths. Twelve (19%) patients had Gr 4 events, and 40 (63%) had Gr 3 events, with 8 hematologic events in each of Gr 3 and Gr 4. The most common Gr 3/4 events were fatigue 8 (13%), neutropenia 5 (8%), and neuropathy 4 (6%). Conclusions: GEMTAX appears to have activity similar to other doublets in metastatic and recurrent SCCHN, with somewhat less toxicity. The tolerability and activity, despite lack of a platinum, suggests that biweekly GEMTAX is a useful combination, warranting further study. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Lilly Lilly
Bronchogenic carcinoma: Clinicopathologic pattern in Nigerians.
Authors: M. A. Salami, P. O. Adeoye, V. Adegboye
Journal: Journal of Clinical Oncology (2010)

e12065 Background: Lung cancer is one of the leading causes of cancer morbidity and mortality. Primary tumors of the lung are supposedly not common in Nigerians. Conflicting reports from Nigeria have failed to uniformly highlight the role of smoking in the aetiopathogenesis. What is however agreed upon in the limited literature from Nigeria is the early age of presentation usually with advanced disease which precludes curative surgical resection in most cases. We sought to examine the current clinical and pathological presentation patterns in the Ibadan Cardiothoracic unit. Methods: This is a longitudinal prospective study of all 18 patients with lung cancer presenting to our institution between August 2008 and July 2009. Clinical information including biodata, clinical features, investigations, treatment and outcome were obtained for each patient. The result was analyzed with SPSS 16. Results: There were 18 patients; 15 were males. The mean age was 54.2 (± 15.9SD). Cough (79%) and dyspnoea (63%) were the most common symptoms. Other symptoms include pleuritic chest pain, weight loss, haemoptysis and hoarsesness of voice. The majority of patients (79%) were non-smokers. The five smokers in the study population were all males. 10 patients had tumour in the right lung and 9 patients had tumour on the left. Histological diagnosis was obtainable in 14 patients with squamous carcinoma being the commonest (10 patients), others were adenocarcinoma (2 patients), and mucoepidermoid carcinoma (1 patient). The other 4 patients had only cytological confirmation of malignancy. Seven of the patients presented with haemorhagic pleural effusion. Survival post-diagnosis ranges from 1 to 8 months. Conclusions: The results of the present study show that lung cancer may no longer be uncommon in Nigerians. This scenario coupled with the common presentation in Middle age and at an advanced stage calls for more awareness in the general population. Time is therefore ripe for multicentre studies of clinical epidemiology of bronchogenic carcinoma in Nigerians. No significant financial relationships to disclose.
Abstract P363: Association of Twenty-Four Hour Urine Calcium Excretion with Cardiovascular Events and Mortality: Data from the Heart and Soul Study
Authors: Christine C Welles, Anne L Schafer, Eric Vittinghoff, Michael G Shlipak, Mary A Whooley, Joachim H Ix
Journal: Circulation (2012)

Background: Recent studies have raised concerns about the cardiovascular (CV) safety of calcium supplementation, particularly in regards to risk of myocardial infarction (MI). However, most prior studies have been limited by imprecise calcium ascertainment using food frequency questionnaires. In contrast, twenty-four hour urinary calcium excretion (UCE) provides an objective, quantitative measure of total daily calcium intake. Therefore, we sought to evaluate the association of UCE with CV events or death in persons with stable coronary heart disease (CHD). Methods: Between 2000-02, 849 subjects with prevalent CHD provided twenty-four hour urine collections and UCE was measured. We used Cox proportional hazards models to evaluate the association of UCE with the composite endpoint of CV events (MI, heart failure, stroke) or all-cause mortality, which were determined by blinded review of medical records. Results: During a mean follow-up of 7 ± 2 years, 374 subjects (44%) had a CV event or died. The mean UCE was 105.7 ± 111.4 mg/day. Following multivariate adjustment for demographics, traditional CV risk factors, and kidney function, there was no association between UCE and the composite of CV events or all-cause mortality ( Table ). Evaluation of individual CV outcomes revealed no association between UCE (entered per 20 mg/day greater urine calcium) and heart failure (HR 1.01, 95% CI 0.98-1.05, p=0.48) or stroke (HR 0.94, 95% CI 0.87-1.02, p=0.13), but a lower rate of MI (HR 0.94, 95% CI 0.89-1.00, p=0.04). The association was similar by sex, presence of chronic kidney disease, and use of calcium supplements (all p interactions &gt; 0.10). Conclusions: Greater UCE is not associated with higher overall CV event rates or mortality in outpatients with stable CHD, and may be associated with a modestly lower rate of MI. These findings suggest that greater daily calcium intake does not confer CV harm in outpatients with prevalent CHD.
Expectoration in the Gastrointestinal Tract A Diagnostic Problem in ln-111 Granulocyte Scintigraphy
Authors: S??REN SCHIFTER, JAN LYSG??RD MADSEN
Journal: Clinical Nuclear Medicine (1990)

Scintigraphic detection of infectious foci with ln-111 labeled granulocytes or leukocytes is a well-established technique in nuclear medicine. The technique is commonly used to demonstrate inflammatory activity in Crohn's disease and ulcerative colitis. Its application, however, may be influenced by infectious expectoration located within the gastrointestinal tract. In performing this technique, it is important to have this differential diagnostic possibility in mind; it can be clarified by repeated imaging.
Preventing penetrating hand injuries in sabre fencing: an application and critique of the van Mechelen model by the Fédération Internationale d'Escrime
Authors: Peter A Harmer
Journal: British Journal of Sports Medicine (2015)

Background/aim To address the unusual phenomenon of unbroken blades causing penetrating hand injuries in sabre fencing by applying the van Mechelen model of the ‘sequence of prevention’. Methods Cases were collected from three surveillance systems and snowball sampling, and examined for potential aetiological factors. Presumed contributing factors were evaluated against the available evidence to compile a viable list for change. Determining a prevention strategy was guided by the philosophy of developing an approach that was most likely to produce a meaningful reduction in these injuries with the least disruption to the current norms of competitive sabre fencing. Results Nine factors which contributed, either individually or in some combination, to these injuries were grouped under three headings relating to: (1) the nature of modern sabre fencing, (2) the design of the sabre blade and (3) the vulnerability of the hand. Changes to the design and integrity of sabre gloves were selected as the most feasible option and new standards were introduced as compulsory in international competitions from 1 April 2014. The effect of this change is now being monitored via available surveillance systems. Conclusions The van Mechelen model is a useful framework for sports federations to apply to reduce injury risk, even for rare injuries. However, this research model has limitations in guiding the realities of sometimes competing interests among the scientific, political, financial and technical aspects of injury prevention interventions.
Abstract 9872: Prognostic Factors of Endovascular Treatment for Femoropopliteal Lesion With Self-expandable Nitinol Stent Longer Than 300mm
Authors: Nobuhiro Suematsu, Yoshimitsu Soga, Mitsuyoshi Takahara, Osamu Iida, Kenji Suzuki, Keisuke Hirano, Daizo Kawasaki, Yoshiaki Shintani, Terutoshi Yamaoka, Taketsugu Tsuchiya
Journal: Circulation (2013)

Purpose: As technical development of catheter devices has progressed, endovascular treatments (EVT) for femoropopliteal (FP) lesions have been increasingly employed in patients with peripheral arterial disease (PAD). In the new era of drug eluting stents, the long term patency of EVT for FP lesions are improving, but there are still obstacles in the treatment of complex lesions such as TASC II D, in terms of the long term patency. In order to clarify the prognostic factors of EVT for an extremely long FP lesion, we have retrospectively analyzed clinical data of patients receiving stents with total length &gt;300mm for de novo FP lesions. Methods: A total of 296 de novo FP lesions which were treated by EVT with self-expandable nitinol bare metal stents with a total length greater than 300mm at 13 hospitals in Japan between January 2004 and December 2011 were retrospectively analyzed. Results: Average patient age was 73.9 years (range 50 to 93), and 180 (68.4%) were male. 157 (59.7%) had diabetes mellitus, and 44 (16.7%) were maintained on hemodialysis. 73 (27.8%) were active smokers and 91 (34.6%) were categorized to Rutherford 4, 5, or 6. All lesions were treated with self-expandable bare metal nitinol stents. Average lesion length was 266.3mm and 3.31 stents (range 1 to 6) were deployed, with average total stent length 318.0mm. During the follow-up period (mean 792.9 days), 42 patients died, of which 35.7% were due to cardiovascular disease. Primary patency rates at 1, 3, and 5 years after treatment, respectively, were 68.4%, 47.8%, and 39.1%, and secondary patency rates were 89.5%, 79.4%, and 74.0%. COX proportional hazard regression analyses revealed that male (0.47 [0.31-0.69], p&lt;0.01), chronic total occlusion (2.19[1.05-4.56], p&lt;0.05), calcified lesions (1.52 [1.01-2.30], p&lt;0.05), cilostazol administration (0.60 [0.42-0.88], p&lt;0.01), and stent fracture (2.26 [1.28-3.98], p&lt;0.01), were significant predictors for primary patency. Conclusion: Even though mid-term primary patency rates of EVT for extremely long FP lesions were needed to be improved, secondary patency rates were mostly acceptable. These data will help guide proper treatment strategies for revascularization of complex FP lesions.
Cutaneous melanoma, staging system.
Authors: L Nathanson
Journal: Journal of Clinical Oncology (1997)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1997.15.8.3026 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 9256150 Cutaneous melanoma, staging system. L NathansonxL NathansonSearch for articles by this author https://doi.org/10.1200/JCO.1997.15.8.3026 PDF "Cutaneous melanoma, staging system.." Journal of Clinical Oncology, 15(8), p. 3026© 1997 by American Society of Clinical Oncology
Phase I Study of Stealth Liposomal Doxorubicin in Combination With Gemcitabine in the Treatment of Patients With Metastatic Breast Cancer
Authors: Edgardo Rivera, Vicente Valero, Laura Syrewicz, Zia Rahman, Francisco L. Esteva, Richard L. Theriault, Marguerite M. Rosales, Daniel Booser, James L. Murray, Robert C. Bast, Gabriel N. Hortobagyi
Journal: Journal of Clinical Oncology (2001)

PURPOSE: We conducted a single-institution phase I clinical trial to determine the maximum-tolerated dose (MTD) and define the toxic effects of stealth liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. PATIENTS AND METHODS: Patients were eligible if they had disease progression with no limit on prior number of chemotherapy regimens. Prior treatment with liposomal doxorubicin and/or gemcitabine was not allowed. The starting dose of liposomal doxorubicin was 20 mg/m 2 on day 1 only with a 20% dose escalation of the previous mg/m 2 dose until MTD was reached. Gemcitabine was given as a fixed dose of 800 mg/m 2 on days 1 and 8 every 3 weeks. RESULTS: We treated 27 patients of whom six had never received chemotherapy for their disease. Most had had visceral involvement as their dominant site of disease. The dose-limiting toxicity was myelosuppression, which included neutropenia and thrombocytopenia. However, neither neutropenic fever nor episodes of bleeding were major occurrences. Significant antitumor activity was also observed with a total of two complete and seven partial responses. The recommended phase II dose is liposomal doxorubicin 24 mg/m 2 on day 1 and gemcitabine 800 mg/m 2 on days 1 and 8 every 21 days. CONCLUSION: The combination of liposomal doxorubicin and gemcitabine is an active and well tolerated regimen when administered on a 21-day schedule. Myelosuppression limited further dose escalation, however, it did not increase the incidence of neutropenic fever. Significant antitumor activity seen in heavily and minimally pretreated patients warrants further evaluation of this combination.
대한간학회 제 8 차 춘계학술대회 초록집 : 만성 B 형 간염에서 Lamivudine 치료 중 발생한 Viral Breakthrough 예의 임상 경과
Authors: 안수현, 오성남, 최도원, 최창원, 조남영, 박종재, 김재선, 박영태, 변관수, 이창홍
Journal: Clinical and Molecular Hepatology (2002)
Hyperinflammation in patients with chronic granulomatous disease leads to impairment of hematopoietic stem cell functions
Authors: Maren Weisser, Uta M. Demel, Stefan Stein, Linping Chen-Wichmann, Fabien Touzot, Giorgia Santilli, Stefanie Sujer, Christian Brendel, Ulrich Siler, Marina Cavazzana, Adrian J. Thrasher, Janine Reichenbach, Marieke A.G. Essers, Joachim Schwäble, Manuel Grez
Journal: Journal of Allergy and Clinical Immunology (2016)
In vitro activity of the HDAC inhibitor Suberoyl anilide hydroxamic acid (SAHA) against gliomas
Authors: Vinay K. Puduvalli, Deepa Sampath, Yuanfang Liu
Journal: Cancer Research (2004)

Proc Amer Assoc Cancer Res, Volume 45, 2004

4171 

Inhibition of histone deacetylase (HDAC) activity is a novel anticancer strategy that has demonstrated potential for inhibiting tumor growth and inducing apoptosis in malignant cells. Suberoyl anilide hydroxamic acid (SAHA) is a potent HDAC inhibitor that has shown activity against several malignancies in preclinical studies and is currently being tested in clinical trials. We assessed the effects of SAHA on glioma cells (Hs683, D54MG and U87MG) and the mechanism of its effects in an in vitro study. A dose- and time-dependent decrease in proliferation was seen in response to SAHA (0.1- 25 μM) in all three cell lines tested. D54MG and U87MG cells exposed to SAHA underwent apoptosis as seen by morphologic changes (nuclear condensation and membrane blebbing), the appearance of a sub-G1 fraction by flow cytometry analysis, and PARP cleavage following Western blot analysis. Decreased anchorage-independent growth was observed in SAHA-treated glioma cells compared with untreated controls in a soft agar clonogenic assay. Concurrent treatment with SAHA and cisplatin or etoposide resulted in more than an additive induction of apoptosis, suggesting synergistic interactions between these agents. The degree of apoptosis was similarly increased when cells were concurrently treated with SAHA and 13 cis-retinoic acid (cRA). These results indicate that SAHA induces apoptosis in glioma cells and acts in a synergistic manner with cytotoxic agents and retinoic acid, suggesting a therapeutic potential for this class of agents against gliomas.
Outcome of Patients Receiving Radiation for Cancer of the Esophagus: Results of the 1992-1994 Patterns of Care Study
Authors: Lawrence R. Coia, Bruce D. Minsky, Brian A. Berkey, Madhu J. John, Daniel Haller, Jerome Landry, Thomas M. Pisansky, Christopher G. Willett, John P. Hoffman, Jean B. Owen, Gerald E. Hanks
Journal: Journal of Clinical Oncology (2000)

PURPOSE: A Patterns of Care Study examined the records of patients with esophageal cancer (EC) treated with radiation in 1992 through 1994 to determine the national practice processes of care and outcomes and to compare the results with those of clinical trials. PATIENTS AND METHODS: A national survey of 63 institutions was conducted using two-stage cluster sampling, and specific information was collected on 400 patients with squamous cell (62%) or adenocarcinoma (37%) of the thoracic esophagus who received radiation therapy (RT) as part of primary or adjuvant treatment. Patients were staged according to a modified 1983 American Joint Committee on Cancer staging system. Fifteen percent of patients had clinical stage (CS) I disease, 40% had CS II disease, and 30% had CS III disease. Twenty-six percent of patients underwent esophagectomy. Seventy-five percent of patients received chemotherapy; 84% of these received concurrent chemotherapy and radiation (CRT). RESULTS: Significant variables for overall survival in multivariate analysis include the use of esophagectomy (risk ratio [RR] = 0.62), the use of chemotherapy (RR = 0.63), Karnofsky performance status (KPS) greater than 80 (RR = 0.61), CS I or II disease (RR = 0.66), and facility type (RR = 0.72). Age, sex, and histology were not significant. Preoperative CRT resulted in a nonsignificantly higher 2-year survival rate compared with definitive CRT alone (63% v 39%; P = .11), whereas 2-year survival by planned treatment rather than treatment given was 47.7% for preoperative CRT and 35.4% for definitive CRT (P = .23). Definitive CRT compared with definitive RT alone resulted in significantly higher 2-year survival (39% v 20.6%; P = .027) and lower 2-year local regional failure (30% v 57.9%; P = .0031). CONCLUSION: This study confirms the value of CRT in EC treatment. It indicates that the results obtained in practice settings nationwide are similar to those obtained in clinical trials and that KPS and the 1983 clinical staging system are useful prognostic indicators. The suggested value of esophagectomy and superiority of preoperative CRT over CRT alone in this study should be tested in a randomized trial.